These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10980159)

  • 1. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
    Livermore DM
    J Antimicrob Chemother; 2000 Sep; 46(3):347-50. PubMed ID: 10980159
    [No Abstract]   [Full Text] [Related]  

  • 2. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin.
    MacConnachie AM
    Intensive Crit Care Nurs; 1999 Aug; 15(4):239-41. PubMed ID: 10786510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report.
    Batts DH; Lavin BS; Eliopoulos GM
    Curr Clin Top Infect Dis; 2001; 21():227-51. PubMed ID: 11572153
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new treatment options for infections due to drug-resistant gram-positive cocci.
    Rehm SJ
    Cleve Clin J Med; 2002 May; 69(5):397-401, 405-13. PubMed ID: 12022383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
    Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
    J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
    Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
    J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for Gram-positive infections.
    Rybak MJ
    J Hosp Infect; 2001 Dec; 49 Suppl A():S25-32. PubMed ID: 11926437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology.
    Wesson KM; Lerner DS; Silverberg NB; Weinberg JM
    Clin Dermatol; 2003; 21(1):64-70. PubMed ID: 12609590
    [No Abstract]   [Full Text] [Related]  

  • 14. New agents for Gram-positive bacteria.
    Bhavnani SM; Ballow CH
    Curr Opin Microbiol; 2000 Oct; 3(5):528-34. PubMed ID: 11050454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid: the first oxazolidinone antimicrobial.
    Johnson JR
    Ann Intern Med; 2003 Nov; 139(10):863; author reply 864. PubMed ID: 14623627
    [No Abstract]   [Full Text] [Related]  

  • 16. [Enterococcus faecium cholangitis resistant to vancomycin and quinupristin-dalfopristin].
    Maseda E; Uña R; Ureta P; Royo C
    Med Clin (Barc); 2002 Sep; 119(7):276-7. PubMed ID: 12236991
    [No Abstract]   [Full Text] [Related]  

  • 17. What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
    Gleckman R
    Postgrad Med; 2001 Mar; 109(3):87-91; quiz 28. PubMed ID: 11265366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
    Erlandson KM; Sun J; Iwen PC; Rupp ME
    Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibiotics--TAZ/PIPC, synercid, linezolid, everninomicin].
    Hidai H
    Nihon Rinsho; 2001 Apr; 59(4):785-9. PubMed ID: 11305007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New anti-Gram+antibiotics: which role in infective endocarditis?].
    Makinson A; Le Moing V
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):88-92. PubMed ID: 18395180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.